133 related articles for article (PubMed ID: 14701826)
1. Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells.
Harwell RM; Mull BB; Porter DC; Keyomarsi K
J Biol Chem; 2004 Mar; 279(13):12695-705. PubMed ID: 14701826
[TBL] [Abstract][Full Text] [Related]
2. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy.
Akli S; Keyomarsi K
Cancer Biol Ther; 2003; 2(4 Suppl 1):S38-47. PubMed ID: 14508079
[TBL] [Abstract][Full Text] [Related]
3. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27.
Wingate H; Zhang N; McGarhen MJ; Bedrosian I; Harper JW; Keyomarsi K
J Biol Chem; 2005 Apr; 280(15):15148-57. PubMed ID: 15708847
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylations of cyclin-dependent kinase 2 revisited using two-dimensional gel electrophoresis.
Coulonval K; Bockstaele L; Paternot S; Roger PP
J Biol Chem; 2003 Dec; 278(52):52052-60. PubMed ID: 14551212
[TBL] [Abstract][Full Text] [Related]
5. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells.
Wingate H; Bedrosian I; Akli S; Keyomarsi K
Cell Cycle; 2003; 2(5):461-6. PubMed ID: 12963845
[TBL] [Abstract][Full Text] [Related]
6. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer.
Akli S; Zheng PJ; Multani AS; Wingate HF; Pathak S; Zhang N; Tucker SL; Chang S; Keyomarsi K
Cancer Res; 2004 May; 64(9):3198-208. PubMed ID: 15126360
[TBL] [Abstract][Full Text] [Related]
7. Indole-3-carbinol (I3C) inhibits cyclin-dependent kinase-2 function in human breast cancer cells by regulating the size distribution, associated cyclin E forms, and subcellular localization of the CDK2 protein complex.
Garcia HH; Brar GA; Nguyen DH; Bjeldanes LF; Firestone GL
J Biol Chem; 2005 Mar; 280(10):8756-64. PubMed ID: 15611077
[TBL] [Abstract][Full Text] [Related]
8. Effects of cyclin D1 overexpression on G1 progression-related events.
Imoto M; Doki Y; Jiang W; Han EK; Weinstein IB
Exp Cell Res; 1997 Oct; 236(1):173-80. PubMed ID: 9344597
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle progression without cyclin E/CDK2: breaking down the walls of dogma.
Gladden AB; Diehl JA
Cancer Cell; 2003 Sep; 4(3):160-2. PubMed ID: 14522248
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.
Pierson-Mullany LK; Lange CA
Mol Cell Biol; 2004 Dec; 24(24):10542-57. PubMed ID: 15572662
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of the Raf/MEK/ERK cascade is necessary and sufficient for activation and Thr-160 phosphorylation of a nuclear-targeted CDK2.
Lents NH; Keenan SM; Bellone C; Baldassare JJ
J Biol Chem; 2002 Dec; 277(49):47469-75. PubMed ID: 12359725
[TBL] [Abstract][Full Text] [Related]
12. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip).
Chen WJ; Chang CY; Lin JK
Biochem Pharmacol; 2003 Jun; 65(11):1777-85. PubMed ID: 12781329
[TBL] [Abstract][Full Text] [Related]
13. Cdc2-cyclin E complexes regulate the G1/S phase transition.
Aleem E; Kiyokawa H; Kaldis P
Nat Cell Biol; 2005 Aug; 7(8):831-6. PubMed ID: 16007079
[TBL] [Abstract][Full Text] [Related]
14. Inducible expression of a degradation-resistant form of p27Kip1 causes growth arrest and apoptosis in breast cancer cells.
Zhang Q; Tian L; Mansouri A; Korapati AL; Johnson TJ; Claret FX
FEBS Lett; 2005 Jul; 579(18):3932-40. PubMed ID: 15996662
[TBL] [Abstract][Full Text] [Related]
15. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.
Yin MB; Guo B; Panadero A; Frank C; Wrzosek C; Slocum HK; Rustum YM
Exp Cell Res; 1999 Feb; 247(1):189-99. PubMed ID: 10047461
[TBL] [Abstract][Full Text] [Related]
16. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes.
Nahum A; Hirsch K; Danilenko M; Watts CK; Prall OW; Levy J; Sharoni Y
Oncogene; 2001 Jun; 20(26):3428-36. PubMed ID: 11423993
[TBL] [Abstract][Full Text] [Related]
17. Limiting amounts of p27Kip1 correlates with constitutive activation of cyclin E-CDK2 complex in HTLV-I-transformed T-cells.
Cereseto A; Washington Parks R; Rivadeneira E; Franchini G
Oncogene; 1999 Apr; 18(15):2441-50. PubMed ID: 10229195
[TBL] [Abstract][Full Text] [Related]
18. Construction of a cyclin D1-Cdk2 fusion protein to model the biological functions of cyclin D1-Cdk2 complexes.
Chytil A; Waltner-Law M; West R; Friedman D; Aakre M; Barker D; Law B
J Biol Chem; 2004 Nov; 279(46):47688-98. PubMed ID: 15355984
[TBL] [Abstract][Full Text] [Related]
19. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells.
Sandhu C; Donovan J; Bhattacharya N; Stampfer M; Worland P; Slingerland J
Oncogene; 2000 Nov; 19(47):5314-23. PubMed ID: 11103932
[TBL] [Abstract][Full Text] [Related]
20. Why are the truncated cyclin Es more effective CDK2 activators than the full-length isoforms?
Rath SL; Senapati S
Biochemistry; 2014 Jul; 53(28):4612-24. PubMed ID: 24947816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
